• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Vibegron Intermediate CAS:1421271-01-3
Food Grade Fish Collagen
Vibegron Intermediate CAS:1295539-30-8
Vibegron Intermediate CAS:1426235-01-9
Vibegron Intermediate CAS:163625-46-5
Vibegron Intermediate

EMA approves Janssen’s Prezista continuous manufacturing line

europeanpharmaceuticalreviewJune 28, 2017

Tag: EMA , Janssen , Manufacturing Line

The European Medicines Agency (EMA) has approved Janssen‘s continuous manufacturing (CM) with real-time release testing for the production of Prezista (darunavir) 600 mg tablets. This process currently occurs on a production line at the company’s manufacturing facility in Gurabo, Puerto Rico.

Below is an infographic, created by Janssen, which speaks to the value of CM in the pharmaceutical industry: (Click to enlarge)

Through strategic innovation and internal and external commercial collaborations, Janssen continues to strengthen its manufacturing capabilities and processes with optimal resource allocation and reduced complexity in order to accelerate the ability to anticipate and respond to customer needs.

In 2016, Janssen became the first in the industry to receive FDA approval to convert from batch to CM. With this EMA approval, Janssen is able to reduce manufacturing and testing cycle time, reduce waste and environmental impact, and lower process risk, all while maintaining existing product quality in the delivery of innovative therapies for patients.

Previous:83% of life science leaders believe blockchain will be adopted within 5 years

Next:Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launc

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

EMA approves Janssen’s Prezista continuous manufacturing line | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

1%2%3%5% Astaxanthin Haematococcus Pluvialis Extract

1%2%3%5% Astaxanthin Haematococcus Pluvialis Extract
Quaternized copolymer of VP/DMAEMA (PQ-11)

Quaternized copolymer of VP/DMAEMA (PQ-11)
Semaglutide

Semaglutide
Demai Physical Cold Pressed Organic Pecan Oil 250ml

Demai Physical Cold Pressed Organic Pecan Oil 250ml
Wellgreen Herb Plant Leaf Powder Pianta Seed Membeli Benih Semilla 25% Kopen Gymnema Sylvestre Extra

Wellgreen Herb Plant Leaf Powder Pianta Seed Membeli Benih Semilla 25% Kopen Gymnema Sylvestre Extra
tert-butyl 3,4-cis-4-amino-3-fluoropiperidine-1-carboxylate racemate

tert-butyl 3,4-cis-4-amino-3-fluoropiperidine-1-carboxylate racemate
Cis-3-fluoro-tetrahydro-2H-pyran-4-amine hydrochloride racemate

Cis-3-fluoro-tetrahydro-2H-pyran-4-amine hydrochloride racemate
21-O-Tigloylgymnemagenin

21-O-Tigloylgymnemagenin
TG12X Microhematocrit Centrifuge

TG12X Microhematocrit Centrifuge
100% Pure Natural preservative Rosemary Extract rosemary acid/rosmarinic acid,rosemary oil,carnosic

100% Pure Natural preservative Rosemary Extract rosemary acid/rosmarinic acid,rosemary oil,carnosic

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service